Efficacy classification of modern therapies in multiple sclerosis

• Published in: Journal of comparative effectiveness research Vol. 10; no. 6; pp. 495 - 507
• Main Authors: Samjoo, Imtiaz A, Worthington, Evelyn, Drudge, Christopher, Zhao, Melody, Cameron, Chris, Häring, Dieter A, Stoneman, Dee, Klotz, Luisa, Adlard, Nicholas
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.04.2021
• Subjects: Antibodies; Bans; cladribine; Classification; Clinical trials; disease-modifying therapy; Drug dosages; Meta-analysis; Monoclonal antibodies; Multiple sclerosis; network meta-analysis; Neurology; ocrelizumab; ofatumumab; ozanimod; Patients; relapsing multiple sclerosis; treatment guidelines; ozanimod; relapsing multiple sclerosis; ocrelizumab; cladribine; ofatumumab; disease-modifying therapy; treatment guidelines; network meta-analysis
• ISSN: 2042-6305; 2042-6313
• DOI: 10.2217/cer-2020-0267

The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.